Ure Utah is the founder of Bridge Synergy and the technical adviser to the Nigerian Honourable Minister of Innovation, Science and Technology on development finance institutions (DFIs) and international partnerships. Her work aims to push Nigeria forward on the international stage with sustainable development in mind.
Pharmaceuticals are a highly competitive and ever-growing industry, and it can be challenging for newcomers to navigate the industry’s niches. But for those looking for somewhere to start, BridgeBio Pharma, a biotech firm based in California, is one of the most exciting companies out there.
In July, BridgeBio announced that Sixth Street had led a preferred equity investment of $1 billion into BridgeBio, with participation from HealthCare Royalty. This represents a substantial vote of confidence in one of biopharma’s most exciting companies.
BridgeBio focuses on rare genetic diseases that require precision medicine. Since its inception over 10 years ago, it has targeted 48 unique disease indicators and has had more than 2,000 patients enrolled in clinical trials around the world.
Underpinning BridgeBio’s success story is its flagship product, Attruby. Attruby is a treatment that stabilizes the TTR protein, which, when unstable, causes buildup in the heart, creating resistance that can lead to hospitalization or death. This drug alone generated $362.4 million in net product revenue for Attruby for the full 2025 year, after its official commercial launch in December 2024.
According to BridgeBio’s Q2 earnings report, Attruby’s sales are going from strength to strength. Attruby’s net product revenue increased by $150.9 million year-on-year, driving significant growth in the company’s revenue against the same quarter of 2025.
It’s easy to see why Attruby’s sales have burgeoned: clinical trials have shown it is a near-complete stabilizer, effective in more than 90% of cases.
And stabilizers like Attruby recently had a big win. Stabilizers have always seen their most direct competition from TTR silencers, but recent clinical trials suggested silencers do little on top of stabilizers to improve patient outcomes. As a result, stabilizers look positioned to become the primary treatment of choice in ATTR-CM cases, setting the stage for a boom in stabilizer sales. BridgeBio’s Attruby, as a near-complete stabilizer, is excellently placed to capitalize on this burgeoning market.
Beyond the Attruby success story, BridgeBio stands out for having a diverse pipeline across genetic disease populations with high unmet needs. This pipeline begins with an extensive research and development program and extends to six other products, three of which are in the third and final stage of development.
One of these, Encaleret for ADH1, has recently made biotech news for coming one step closer to market. This treatment was designed to address a common form of genetic hypoparathyroidism, which causes calcium sensitivity, imbalances in the blood and urine, and an increased likelihood of kidney calcification, kidney stones, and kidney failure. Encaleret has shown a promising ability to target low calcium levels in blood and high calcium in urine, prompting the FDA to accept its NDA. The FDA’s NDA acceptance signals “a powerful validation of Encaleret’s differentiated clinical profile and enables a major step forward for the ADH1 community.”
This has come directly off the back of FDA’s NDA acceptance of another one of BridgeBio’s treatments earlier this year: the BBP-418 treatment for Limb-Girdle Muscular Dystrophy, an illness that impacts over 7,000 people in the US and Europe. The condition causes sugar molecules to attach to protein, which eventually damages muscle cells. This causes a loss of muscle mass and weakness in muscles, including cardiac and respiratory muscles. Once again, the priority review of BridgeBio’s NDA in late May proved to be a milestone in the company’s journey to create the first and only approved therapy for people living with this disease.
While BridgeBio has historically been predominantly associated with its Attruby ATTR-CM treatment, no single drug would be enough on its own to encourage a $1 billion investment; it is BridgeBio’s larger pipeline and broader strategic position that proves it will not be a one-hit-wonder. Unsurprisingly, BridgeBio has caught the interest of big industry players that want to be a part of its growth.
